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Vascular endothelial growth factor C (VEGF-C) is a lymphangiogenic factor over-expressed in highly metastatic, cyclooxygenase
(COX)-2 expressing breast cancer cells. We tested the hypothesis that tumour-derived VEGF-C may play an autocrine role in
metastasis by promoting cellular motility through one or more VEGF-C-binding receptors VEGFR-2, VEGFR-3, neuropilin (NRP)-1,
NRP-2, and integrin a9b1. We investigated the expression of these receptors in several breast cancer cell lines (MDA-MB-231,
Hs578T, SK-BR-3, T-47D, and MCF7) and their possible requirement in migration of two VEGF-C-secreting, highly metastatic lines
MDA-MB-231 and Hs578T. While cell lines varied significantly in their expression of above VEGF-C receptors, migratory activity of
MDA-MB-231 and Hs578T cells was linked to one or more of these receptors. Depletion of endogenous VEGF-C by treatments
with a neutralising antibody, VEGF-C siRNA or inhibitors of Src, EGFR/Her2/neu and p38 MAP kinases which inhibited VEGF-C
production, inhibited cellular migration, indicating the requirement of VEGF-C for migratory function. Migration was differentially
attenuated by blocking or downregulation of different VEGF-C receptors, for example treatment with a VEGFR-2 tyrosine kinase
inhibitor, NRP-1 and NRP-2 siRNA or a9b1 integrin antibody, indicating the participation of one or more of the receptors in cell
motility. This novel role of tumour-derived VEGF-C indicates that breast cancer metastasis can be promoted by coordinated
stimulation of lymphangiogenesis and enhanced migratory activity of breast cancer cells.
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Vascular endothelial growth factor (VEGF)-C is the major
lymphangiogenic factor which is expressed in certain normal
tissues, for example large intestinal and mammary duct epithelia,
skeletal and cardiac muscle, thyroid, ovary, and prostate (Joory
et al, 2006) as well as in a variety of cancerous tissues including
breast cancer (Kinoshita et al, 2001; Nakamura et al, 2003, 2005,
2006). Over-expression of VEGF-C in the tumour micro-environ-
ment has been reported to be associated with a poor prognosis
(Nakamura et al, 2003; Mylona et al, 2007) and lymph node
metastasis (Nakamura et al, 2005) in breast cancer patients.
Although tumour-associated macrophages were reported to be a
major source of VEGF-C in breast cancer (Schoppmann et al,
2006), we have recently discovered that cyclooxygenase (COX)-2
expressing, highly metastatic human breast cancer cells themselves
secrete a copious amount of this factor in cell culture medium
(Timoshenko et al, 2006). Tumour-derived VEGF-C is thought to
promote tumour progression by inducing lymphangiogenesis and
thereby lymph node metastasis (Saharinen et al, 2004; Timoshenko
et al, 2006; Tobler and Detmar, 2006). As a lymphangiogenic
factor, VEGF-C acts through activation of the tyrosine kinase
receptor VEGFR-3 expressed by lymphatic endothelial cells
(Saharinen et al, 2004). VEGF-C, however, can also bind to several
other important cell membrane receptors such as VEGFR-2 (a
major angiogenic receptor) (Joukov et al, 1996), neuropilin (NRP)-
1 and NRP-2 (receptors for semaphorins) (Ka ¨rpa ¨nen et al, 2006),
and a9b1 integrin (Vlahakis et al, 2005), a receptor for
osteopontin, tenascin-C, and VCAM-1 (Marcinkiewicz et al,
2000). Expression of all these receptors, although typically noticed
on endothelial cells, has also been reported in other cell types
including tumour cells (Fitzpatrick et al, 2003; Vantyghem et al,
2005; Favier et al, 2006). These observations suggest that in
addition to the major lymphangiogenic function, VEGF-C may
play a role as an autocrine molecule directly affecting functions of
certain cancer cells which express any of these VEGF-C-binding
receptors.
Migration of cancer cells is an essential step for invasion and
metastasis and can be promoted in an autocrine manner by
various endogenous factors including VEGF-A (Dias et al, 2000;
Bachelder et al, 2002). Recently, exogenous VEGF-C was shown to
promote migration of Kaposi’s sarcoma cells which expressed
VEGFR-2 and VEGFR-3 (Marchio et al, 1999). NRP-2 can
contribute to cell migration in collaboration with VEGFR-2 and
VEGFR-3; NRP-2 ligand semaphorin-3F and NRP siRNA both
inhibited the response of human microvascular endothelial cells
(HMVEC) to VEGF-A and VEGF-C (Favier et al, 2006). The role of
NRP-1 in migration was also demonstrated for a human colon
adenocarcinoma cell line WiDR, which showed a significant drop
in migratory activity after transfection with NRP-1 siRNA
Received 18 July 2007; revised 16 August 2007; accepted 23 August
2007; published online 2 October 2007
*Correspondence: Professor PK Lala; E-mail: pklala@uwo.ca
British Journal of Cancer (2007) 97, 1090–1098
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s(Ochiumi et al, 2006). The principal demonstrated function of
a9b1 integrin is acceleration of leucocyte migration, an effect that
depends on unique sequences within the a9 cytoplasmic domain
(Shang et al, 1999; Young et al, 2001; Chen et al, 2004). This
integrin is over-expressed in an aggressive human breast cancer
cell line 468LN capable of producing lymph node metastasis in
nude mice (Vantyghem et al, 2005), suggestive of participation of
VEGF-C. It has remained, however, unknown whether and how
VEGF-C-binding receptors participate in mediating migration of
VEGF-C-producing breast cancer cells.
We have shown that COX-2-mediated VEGF-C upregulation in
human breast cancer served as a stimulus for lymphangiogenesis, a
vehicle for lymphatic metastasis (Timoshenko et al, 2006). In that
study, we found that high COX-2 expressing human breast cancer
cells produced much higher levels of VEGF-C than VEGF-A.
Present study was designed to explore a possible autocrine role of
VEGF-C in breast cancer cell migration, including a systematic
analysis of expression and migration-associated function of VEGF-
C-binding receptors in a number of human breast cancer cell lines.
MATERIALS AND METHODS
Reagents
PP1 (Src kinase inhibitor) was purchased from Biomol (Plymouth
Meeting, PA, USA). SU5416 (VEGFR-2 tyrosine kinase inhibitor),
and Sigma FAST 3,30-diaminobenzidine tablet sets were from
Sigma (Oakville, ON, Canada). PD153035 (EGFR and Her2/neu
tyrosine kinase inhibitor) and SB203580 (p38 kinase inhibitor)
were from Calbiochem (San Diego, CA, USA). NRP-1 and NRP-2
siRNA duplexes, goat polyclonal anti-human VEGF-C antibody
(sc-1881), and normal goat immunoglobulin G (IgG) (sc-2028)
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Rabbit polyclonal anti-human VEGFR-2 antibody (cat. no. 2479)
was from Cell Signaling (Danvers, MA, USA). DMEM, aMEM, fetal
bovine serum (FBS), Ca
2þ,M g
2þ-free Dulbecco’s phosphate-
buffered saline (DPBS), TRIzol reagent and SuperScript II reverse
transcriptase were from Invitrogen (Burlington, ON, USA). VEGF-
C siGENOME SMARTpool of four siRNA duplexes, siCONTROL
non-targeted siRNA, and DharmaFECT 2 transfection reagent were
from Dharmacon (Lafayette, CO, USA). Mouse anti-integrin a9b1
monoclonal antibody (clones Y9A2, cat. no. MAB2078Z), goat anti-
mouse IgG conjugated to R-phycoerythrin (cat. no. AQ196H), and
negative isotype control for flow cytometry mouse IgG1 (cat. no.
CBL600) were from Chemicon International (Temecula, CA, USA).
Human breast cancer cell lines
The original source of all human breast cancer cell lines (MDA-
MB-231, Hs578T, MCF7, T-47D, and SK-BR-3) was the ATCC
(Manassas, VA, USA) excepting 468LN which was kindly provided
by Dr Ann Chambers (London Regional Cancer Program, London,
ON, Canada). This cell line was derived by Dr Chambers’ group by
in vivo selection of MDA-MB-468 cancer cell line for lymphatic
metastasis (Vantyghem et al, 2005). All cell lines were maintained
in DMEM supplemented with 10% FBS, 25mM HEPES buffer,
50Uml
 1 penicillin, and 50mgml
 1 streptomycin except for
468LN, in which case DMEM was replaced with aMEM, and SK-
BR-3, in which case DMEM was replaced with McCoy’s 5A medium
(modified).
RT–PCR
Total RNA was extracted from breast cancer cells grown in 6-well
plates by TRIzol reagent and cDNAs were synthesised using
SuperScript II Reverse Transcriptase as described elsewhere
(Timoshenko et al, 2006). Primers for VEGFR-2, VEGFR-3, NRP-
1, NRP-2, VEGF-C, and GAPDH (Table 1) were synthesised locally
at the UWO Oligo Factory (London, ON, Canada) and their quality
was verified by a conventional PCR using GeneAmp PCR System
from Perkin Elmer (Norwalk, CT, USA) based on standard
amplification conditions: 30–35 cycles of denaturation at 941C
(30s), annealing at 551C (30s), extension at 721C (45s) followed by
5min of final extension at 721C. Real-time quantitative PCR
(qPCR) was performed in single microcapillary tubes using the
LightCycler (Roche Diagnostic, Laval, Que., Canada) and SYBR
Green Tag ReadyMix (Sigma, Oakville, ON, Canada) as previously
described (Timoshenko et al, 2006). All data were normalised
relative to the expression of GAPDH mRNA in respective samples.
siRNA transfection
All siRNA transfection experiments were performed in antibiotic-
free medium with cells grown in 6-well plates. The cells (1.5 10
5
cells per well) were plated overnight at 371C, 5% CO2 and then
transfected with 100nM of either siControl non-targeting siRNA or
target-specific siRNAs to knock-down VEGF-C, NRP-1, or NRP-2
in the presence of 0.2% of DharmaFECT 2. The efficiency of
transfection was assayed by qPCR or conventional PCR and, in
addition, by ELISA for VEGF-C protein secretion.
Flow cytometry
Flow cytometry analysis was performed based on the staining
procedure described elsewhere (Vantyghem et al, 2005). Cells were
grown up to 80% confluency in T75 flasks, gently dislodged with
Trypsin-EDTA solution (0.5% trypsin, 0.48mM EDTA 4Na in
DPBS), centrifuged and resuspended in 2% FBS/DPBS flow buffer.
All following steps were performed at 41C or on ice. Aliquots of
unfixed cells in flow buffer (100ml, 10
6 cells) in Eppendorf tubes
were incubated subsequently with mouse anti-a9b1 integrin
primary antibody or isotype-matched control mouse IgG1 (1mg
per 10
6 cells) and secondary antibody labelled with R-phycoery-
thrin (0.5mg per 10
6 cells) for 1h every time on a rotating plate in a
dark. Following every treatment, the cells were washed twice in
1ml of flow buffer (4min, 230g) on a centrifuge Allegra X-22R
from Beckman Coulter (Mississauga, ON, Canada). Finally, the
stained cells (1ml in flow buffer) were filtered through 40mm
nylon cell strainers from BD Biosciences (Bedford, MA, USA) and
Table 1 Oligonucleotide primer pairs for RT–PCR
Gene (accession #) Forward primer sequence, 50-30 (positions) Reverse primer sequence, 50-30 (positions) Product size (bp)
VEGF-C (NM_005429) CGGGAGGTGTGTATAGATGTG (830–850) ATTGGCTGGGGAAGAGTTTG (1412–1393) 583
VEGFR-2 (NM_002253) CAATGGAGGGGAACTGAAGAC (2679–2699) TCTGGCTACTGGTGATGCTGT (3214–3194) 536
VEGFR-3 (NM_002020) GAGCAGCCATTCATCAACAAG (427–447) GGTAGTCCCAGTCAAAGGTG (826–807) 400
NRP-1 (NM_003873) GATACGAAGGTGAAGGAG (3019–3036) TATAGTTCTCCAGGGCAG (3222–3205) 204
NRP-2 (NM_201279) GCAGATGAATACGAGGTG (3213–3230) GCAGCACTTTTGGTGGTT (3509–3492) 297
GAPDH (NM_002046) ACCACAGTCCATGCCATCAC (628–647) TCCACCACCCTGTTGCTGTA (1079–1060) 452
VEGF¼Vascular endothelial growth factor; NRP¼neuropilin.
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CA, USA) at the London Regional Flow Cytometry Facility
(Robarts Research Institute, London, ON, Canada).
Migration (chemokinesis) assay
The migration of MDA-MB-231 and Hs578T cells through
polycarbonate membranes (having 8mm diameter pores) in 24
well Transwell cell culture chambers (Corning Costar Corporation,
Cambridge, MA, USA) was quantified as described elsewhere
(Timoshenko et al, 2003) with minor modifications. Briefly, 20000
cells in an antibiotic-free DMEM supplemented with 0.1% FBS and
respective treatments were placed in the upper insert and allowed
to migrate for 24h at 371C in a humidified CO2 incubator; the
bottom well was filled with the same solution used to resuspend
cells. Cells that migrated and adhered to the bottom surface of the
membranes were fixed with methanol (2min) and stained for
5min each with eosin and thiazine using Hemacolor kit from EM
Science (Gibbstown, NJ, USA). The stained membranes were cut
out, placed on a glass slide, and the number of migrant cells on the
bottom surface of the membrane was counted using a bright field
light microscope. The migrant cell number in the experimental
(treated) wells expressed as a percentage of the control (untreated)
wells provided the migration index. Each treatment was performed
in triplicate or quadruplicate.
Immunostaining for VEGFR-2
MDA-MB-231 cells were grown up to subconfluency on Lab-Tek
Permanox slides with four chambers from Nalge Nunc (Naperville,
IL, USA). The cell monolayers were rinsed with DPBS, fixed in 2%
formaldehyde for 15min, rinsed again 3 times with DPBS, and
blocked with diluted goat normal serum for 1h at room
temperature. Primary polyclonal rabbit anti-VEGFR-2 antibody
was diluted 1:100 in DPBS containing 0.3% triton X-100 and
added to every chamber (500ml per well) for overnight incubation
at 41C. Then the cells were rinsed 3 times with DPBS and the
VECTASTAIN Elite kit from Vector Laboratories (Burlingame, CA,
USA) was applied to stain samples according the manufacturers’
protocol. To visualise the sites of immunostaining, 3,30-diamino-
benzidine/urea hydrogen peroxide substrate solution was used
and, finally, the samples were counterstained with Harris’ alum
hematoxylin (EMD Chemicals, Darmstadt, Germany) and mounted
with Faramount (DakoCytomation, Glostrup, Denmark).
Statistics
Data were analysed by two way ANOVA and Student’s T-test
considering Po0.05 as an indicator of significant difference
between means.
RESULTS
VEGF-C function blocking antibody, VEGF-C siRNA, and
VEGF-C synthesis inhibitors inhibit migration of human
breast cancer cells
As we have recently reported, highly metastatic MDA-MB-231 and
Hs578T cells secrete a relatively high amount of VEGF-C in cell
culture medium (Timoshenko et al, 2006). To find out whether
migration of these human breast cancer cell lines depends on
endogenously produced VEGF-C, we used three different ap-
proaches, namely (1) the treatment of cells with a VEGF-C
neutralising/function blocking antibody, (2) transfection of cells
with VEGF-C siRNA to downregulate gene expression, and (3) the
treatment of cells with kinase inhibitors for EGFR/Her2/neu
PD153035), Src (PPI), and p38 MAPK (SB203580) at non-toxic
concentrations which have recently been shown to inhibit VEGF-C
production by MDA-MB-231 cells (Timoshenko et al, 2006).
First of all, we screened several commercially available anti-
human VEGF-C antibodies for function blocking activity and
found that a polyclonal goat antibody raised against the C
terminus of VEGF-C of human origin (Santa Cruz, CA, USA)
was active, similar to its blocking activity reported on coronary
endothelial tube formation from embryonic cardiac explants
(Tomanek et al, 2002). In view of the fact that this antibody
recognises the VEGF-C propeptide as well as several cleaved
products inclusive of the C terminus (Siegfried et al, 2003; Tang
et al, 2003), the VEGF-C function blocking activity of this antibody
is possibly attributed to a protection of the antigen–antibody
complex from further proteolytic cleavage that would generate
VEGF-C peptides capable of activating VEGF-C receptors. Using
this antibody, we treated COX-2/VEGF-C-expressing MDA-MB-
231 and Hs578T cells at different concentrations (0–20mgml
 1)
and allowed them to migrate for 24h at 371C. A significant
(Po0.001) decrease in migration resulted from the antibody
treatment of both cell lines at concentrations of 5mgml
 1 and
higher, whereas control goat IgG at similar concentrations had no
effect (Figures 1A and B). In contrast, at similar antibody
concentrations, no significant effect was noted on cell prolifera-
tion/survival (MTT assay) at 24h (not shown). Thus, secreted
VEGF-C is an important factor maintaining the migratory (but not
proliferative) function of these breast cancer cell lines.
Secondly, to silence VEGF-C gene expression, MDA-MB-231
cells were transfected with VEGF-C siRNA (100nM) and the
following three parameters were examined: VEGF-C mRNA
expression (Figure 1C), VEGF-C proteins secretion (Figure 1D),
and cell migration (Figure 1E). In all cases, we observed a
significant drop of every parameter when the specific siRNA-
transfected cells were compared with either mock-transfected
control or scrambled siRNA treated cells. The inhibition of
cell migration, although significant, was rather moderate in
comparison with the effect of neutralising antibody, evidently
due to the fact that VEGF-C production could not be completely
knocked-down. Nevertheless, the migration-inhibitory effects
of VEGF-C siRNA on VEGF-C producing MDA-MB-231 cells
strongly supports the migration-promoting role endogenous
VEGF-C.
Finally, we treated MDA-MB-231 cells with PD153035 (EGFR
and Her2/neu tyrosine kinase inhibitor), PP1 (Src kinase
inhibitor), and SB203580 (p38 MAP kinase inhibitor) which had
earlier been shown to significantly inhibit VEGF-C secretion by
this cell line at the respective concentrations without any effect on
cell proliferation/survival (Timoshenko et al, 2006). As shown in
Figure 1F, all these inhibitors at non-toxic concentrations known
to inhibit VEGF-C secretion (Timoshenko et al, 2006) also
inhibited the migration of MDA-MB-231 cells in a parallel manner
at a 24h time point. The data suggest that these kinases are
important for both the cellular events (VEGF-C secretion and cell
migration) or for the event of VEGF-C secretion, which in turn,
regulated cellular migration. While on their own, these data do not
prove the autocrine role of VEGF-C in cellular migration, they are
supportive of earlier experiments using the function blocking
antibody and VEGF-C siRNA.
Since VEGF-C can act through different VEGF-C-binding
receptors, the next issue was to determine the expression and
the role of specific receptors in mediating migratory responses in
breast cancer cells.
Expression of VEGF-C-binding receptors in human breast
cancer cell lines
The biological action of VEGF-C can be mediated theoretically
through two tyrosine kinase receptors VEGFR-2 and VEGFR-3
(Joukov et al, 1996), NRP-1 and-2 (Ka ¨rpa ¨nen et al, 2006), and a9b1
VEGF-C and breast cancer cell migration
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receptors may be instrumental for autocrine effects of VEGF-C, we
analysed their mRNA or protein expression in five human breast
cancer cell lines (MCF-7, T-47D, SK-BR-3, Hs578T, and MDA-MB-
231), which differ in their expression of COX-2 and VEGF-C
(Timoshenko et al, 2006).
Non-metastatic, COX-2-negative, poorly migratory and low
VEGF-C secreting MCF-7 cells as well as moderately COX-2
expressing and VEGF-C secreting Hs578T cells expressed neither
detectable VEGFR-2 nor VEGFR-3 mRNA (Figure 2A). Low COX-2
expressing and VEGF-C secreting T-47D cells expressed VEGFR-3
but not VEGFR-2 mRNA, whereas high COX-2 expressing and
VEGF-C secreting, highly migratory/invasive and metastatic MDA-
MB-231 cells expressed VEGFR-2 but not VEGFR-3 mRNAs
(Figure 2A). Thus, the expression of VEGFR-2 and VEGFR-3 bore
no relationship to the level of COX-2 expression or VEGF-C
secretory ability of breast cancer cell lines. The VEGFR-2 protein
expression was confirmed in highly metastatic MDA-MB-231 cells
by immunocytochemistry (Figure 2B).
With regard to NRPs, the expression of NRP-1 mRNA was
found to be ubiquitous in all the tested human breast cancer
cell lines, whereas NPR-2 mRNA was expressed only by high
COX-2 and VEGF-C expressing MDA-MB-231 and Hs578T cells
(Figure 2C).
To screen the expression of a9b1 integrin, we used flow
cytometry analysis of several human breast cancer cell lines,
inclusive of a high a9b1 integrin-expressing 468LN cell line
(Vantyghem et al, 2005), used as a positive control. Figure 2D
shows that all the tested human breast cancer cell lines (MDA-MB-
231, Hs578T, SK-BR-3, T-47D, and MCF7) expressed relatively low
levels of a9b1 integrin in comparison with 468LN. Thus, the ratio
of geometric means of fluorescence intensity for cell population
treated with anti-a9b1 integrin primary antibody to those treated
with isotype-matched normal mouse IgG1 were 170 for 468LN, 5.5
for T-47D, 4.7 for SK-BR-3, 3.5 for MCF7, 3.1 for Hs578T, and 2.7
for MDA-MB-231.
Thus, human breast cancer cell lines are heterogeneous in their
expression of different VEGF-C-binding receptors, which can
potentially mediate autocrine action of VEGF-C including its
ability to stimulate cell migration, as documented in other cell
types, for example endothelial cells (Makinen et al, 2001), lung
cancer cells (Tanno et al, 2004), Kaposi’s sarcoma cells (Marchio
et al, 1999), and leucocytes (Shang et al, 1999; Young et al, 2001;
Chen et al, 2004).
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Figure 1 (A and B) Effects of different concentrations of a polyclonal, function blocking antibody against human Vascular endothelial growth factor
(VEGF)-C on migration of VEGF-C-secreting MDA-MB-231 and Hs578T cells cultured for 24h in serum-free DMEM supplemented with 0.1% FBS. A strong
inhibition of migration (Po0.02), noted at all antibody concentrations ranging between 5 and 20mgml
 1, and no inhibition with similar concentrations of
control goat immunoglobulin G (IgG), indicated an autocrine migration-promoting role of VEGF-C in these cells. (C) Effects of siVEGF-C (100nM)
treatments on the expression of VEGF-C gene in MDA-MB-231 cells (48h). (D) VEGF-C secretion from MDA-MB-231 cells transfected with siVEGF-C
(100nM, 48h) which were incubated in serum-free DMEM for other 24h. (E) Migration of MDA-MB-231 cells is inhibited by transfection with siVEGF-C
(100nM) as measured at 24h time point in DMEM supplemented with 0.1% FBS. (F) Effects of kinase inhibitors for EGFR/Her2/Neu (PD153035), Src (PP1),
and p38 MAPK (SB203580) on migration of MDA-MB-231 cells cultured for 24h in DMEM supplemented with 0.1% FBS. Data represent mean±s.d.
(n¼4). *Po0.01. All the above kinase inhibitors at the tested non-toxic concentrations had no significant effect on cell proliferation/survival and inhibited
VEGF-C production, as we reported earlier (Timoshenko et al, 2006).
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Since MDA-MB-231 cells secreted the highest level of VEGF-C
(Timoshenko et al, 2006) and expressed both VEGFR-2 mRNA and
protein (Figure 2A and B), we tested the role of this receptor in cell
migration using a selective pharmacological inhibitor of VEGFR-2
tyrosine kinase SU5416 (Fong et al, 1999). Treating cells with SU
5416 resulted in a concentration-dependent inhibition of cellular
migration without any significant effect on cell proliferation/
survival, indicating the requirement of VEGFR-2 in migratory
function of these cells (Figure 3). In particular, at a concentration
of 4mM and higher SU5416 inhibited migration of MDA-MB-231
cells at 24h by approximately 80% (Po0.001). The specificity of
SU5416 was further validated by the fact that VEGFR-2 negative
Hs578T cells showed very minor inhibitory response to SU5416
(Figure 3). These results affirm the role of one or more of the
autocrine ligands (VEGF-A, VEGF-C) interacting with VEGFR-2 in
migration promotion of MDA-MB-231 cells. It is also possible that
receptor(s) other than VEGFR-2 may also be involved. With this
point in mind, we analysed the role of NRP-1 and NRP-2 which are
expressed in MDA-MB-231 and HS578T cells.
Contribution of NRP-1 and NRP-2 to migration of human
breast cancer cells
To evaluate the contribution of these receptors in the migration of
VEGF-C-secreting MDA-MB-231 and Hs578T cells, we measured
the migratory activity of these cells after transfection with
respective siRNAs. As shown in Figure 4A, siNRP-1 and siNRP-2
specifically silenced the expression of NRP-1 and NRP-2 mRNAs
in both cell lines. The migration of VEGFR-2 expressing MDA-
MB-231 cells was inhibited moderately after siRNA-mediated
knock-down of either NRP-1 or NRP-2 genes whereas no
migration-inhibitory effect of siRNA treatment was noted in the
case of VEGFR-2-negative Hs578T cells (Figure 4B).
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Figure 2 (A) Expression of VEGFR-2 and VEGFR-3 mRNA in human breast cancer cells (MCF-7, T-47D, Hs578T, and MDA-MB-231) and a human
trophoblast cell line (HTR-8/SVneo, used as a positive control for VEGFR-3) as revealed by RT–PCR. MDA-MB-231 cells express VEGFR-2 (binding to
VEGF-A and -C) but not VEGFR-3 (binding to VEGF-C and -D). MCF-7 and Hs578T cells expressed none of these receptors, whereas T-47D expressed
VEGFR-3. (B) Immunostaining of MDA-MB-231 cells for VEGFR-2 (image on the left) and its control (image on the right), cells counterstained with
hematoxylin and eosin (H&E). (C) Expression of neuropilin (NRP)-1 and NRP-2 mRNAs in human breast cancer cell lines MCF-7, MDA-MB-231, Hs578T,
SK-BR-3, and T-47D as revealed by RT–PCR. (D) Flow cytometry analysis of various human breast cancer cells (468LN, MDA-MB-231, Hs578T, SK-BR-3,
MCF7, and T-47D) labelled with a9b1 integrin antibody. In comparison with strongly a9b1 integrin positive 468LN cells (15), other cell lines demonstrated
relatively low levels of a9b1 integrin expression (filled profiles) overlapping partially with non-specific isotype control staining (opened profiles).
Approximately 20000 cells were analysed in each case.
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breast cancer cells
To test the role of a9b1 integrin in migration of MDA-MB-231 and
Hs578T cells (both of which expressed this integrin at low levels),
we analysed their migration in the presence of two concentrations
of mouse anti-integrin a9b1 monoclonal antibody (1 and
5mgml
 1). This antibody was reported to inhibit VEGF-C/-D-
mediated migration of a9-transfected mouse embryonic cells and
primary adult human dermal microvascular endothelial cells
(Vlahakis et al, 2005). As noted in Figure 5, migration of Hs578T
cells but not MDA-MB-231 cells was significantly inhibited in the
presence of the antibody at a concentration of 5mgml
 1.
DISCUSSION
Present study, to our knowledge, is the first one to demonstrate the
autocrine role of VEGF-C in promoting human breast cancer cell
migration, a critical step for invasion and metastasis. The
migration-stimulating role of endogenous VEGF-C was demon-
strated with two approaches: use of neutralising antibody and
silencing of VEGF-C gene with siRNA. The third approach of
inhibition of VEGF-C production by certain signalling inhibitors
provided further support to these data. These findings are highly
relevant for human breast cancer progression and metastasis
because of two reasons: (a) we have shown that VEGF-C is the
dominant product of highly metastatic human breast cancer cells
amongst various members of the VEGF family, upregulated by
COX-2 – an important marker for breast cancer progression
(Timoshenko et al, 2006); (b) VEGF-C expression in human breast
cancer is associated with poor prognosis (Nakamura et al, 2003;
Mylona et al, 2007). Thus, VEGF-C plays a dual role in promoting
breast cancer progression: a stimulation of lymphangiogenesis and
thereby lymphatic metastasis (Saharinen et al, 2004; Timoshenko
et al, 2006; Tobler and Detmar, 2006), and a direct action on cancer
cells in stimulating cellular migratory function. Indeed, our recent
studies of quantitative immunocytochemistry of VEGF-C protein
expression in human breast cancer cells in situ revealed no
significant difference of expression levels between lymph node
positive and negative specimens, suggesting additional lymphan-
giogenesis-independent role(s) of VEGF-C (Lala et al, 2007). We
have further shown in the present study that the autocrine
migration stimulatory role of VEGF-C is mediated by multiple
VEGF-C receptors expressed by breast cancer cells. It is highly
likely that breast cancer cells in situ are also heterogeneous in
expression of different VEGF-C receptors, similar to the breast
cancer cell lines employed in the present study, and the receptor
bearing cells would respond to both endogenous and exogenous
(produced by other cells such as macrophages (Schoppmann et al,
2006) in the breast cancer stroma) VEGF-C in the tumour
microenvironment.
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Figure 4 (A) Silencing of neuropilin (NRP)-1 and neuropilin (NRP)-2
mRNA expression in MDA-MB-231 and Hs578T cells transfected with
100nM of respective siRNAs for 48h (see Material and Methods). The
RT–PCR data demonstrated a highly specific knock-down of both genes.
(B) Migration of untreated (mock-transfected control) and NRP-1 and
NRP-2 siRNA-transfected MDA-MB-231 and Hs578T cells. Whereas both
siRNAs inhibited (*Po0.05) migration of VEGFR-2-expressing MDA-MB-
231 cells, the migratory activity of transfected Hs578T cells was not
impaired.
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Figure 5 Effects of a9b1 integrin function-blocking antibody on
migration of MDA-MB-231 and Hs578T breast cancer cells at a 24h.
The antibody (1 and 5mgml
 1) caused a concentration dependent
inhibition of migration of Hs578T but not MDA-MB-231 cells. *Po0.05.
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Figure 3 Effect of SU5416, a selective inhibitor of VEGFR-2 (Flk-1/KDR)
tyrosine kinase, on migration of MDA-MB-231 and Hs578T cells cultured
for 24h in DMEM supplemented with 0.1% FBS. Data represent
mean±s.d. (n¼3). *Po0.02. The migration of VEGFR-2 expressing
MDA-MB-231 cells was strongly inhibited at inhibitor concentrations
X2mM, while only a very minor effect was noted with VEGFR-2-negative
Hs578T cells.
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receptors as crucial regulators of vasculogenesis, angiogenesis,
lymphangiogenesis, and vascular permeability have been well
documented during last decade (Roy et al, 2006; Shibuya and
Claesson-Welsh, 2006). While VEGF-C has not been described
before as an autocrine factor in promoting tumour progression,
recent studies in a variety of tumours have reported angiogenesis-
independent roles of VEGF-A, another important member of the
VEGF family, in promoting tumour cell proliferation/survival
and migration. For example, an autocrine function of VEGF-A has
been demonstrated for the following: growth and migration of
leukaemia cells (Dias et al, 2000), proliferation of Kaposi’s
sarcoma, melanoma, and ovarian carcinoma cell lines (Masood
et al, 2001), proliferation of interleukin 6-treated prostate cancer
cells (Steiner et al, 2004), growth of a human gastric adenocarci-
noma cell line MGC803 (Tian et al, 2001), and of malignant pleural
mesothelioma (Strizzi et al, 2001). Finally, VEGF-A has been show
to promote survival, migration, and invasiveness of breast cancer
cells (Mercurio et al, 2005). The receptor responsible for many of
the VEGF-A actions cited above has been identified as VEGFR-2,
which can also serve as a receptor for VEGF-C (McColl et al, 2004).
The 21kDa peptide derived after full processing of VEGF-C is the
only VEGF-C peptide capable of activating VEGFR-2 (Joukov et al,
1997), and this peptide has been demonstrated in the conditioned
medium of MDA-MB-231 cells (Nakamura et al, 2006) which we
have shown to express VEGFR-2 but not VEGFR-3. In the present
study, migration inhibition in the presence of the VEGFR-2
inhibitor may be due to the presence of either of the endogenous
ligands, VEGF-A, or VEGF-C. While the roles of VEGF-A in
tumour progression have received a lot of attention, less attention
has been devoted to VEGF-C. In situations, where the VEGF-A/
VEGF-C balance in the tumour microenvironment is shifted in
favour of VEGF-C, the VEGF-C-mediated responses would likely
dominate. For example, higher serum concentrations of VEGF-C
than that of VEGF-A, believed to be tumour derived, correlates
with lymph node metastasis in patients with squamous cell
carcinoma of the oesophagus (Krzystek-Korpacka et al, 2007).
The rate of secretion of VEGF-C in vitro by the highly metastatic
human breast cancer cell line MDA-MB-231 was found to be 10
times than that of VEGF-A (Timoshenko et al, 2006). Whether this
is true for COX-2 expressing breast cancer in vivo remains
unknown at present.
While the traditional endothelial cell receptors for VEGF-C are
VEGFR-3 and VEGFR-2, respectively, responsible for lymphangio-
genic and angiogenic events, recently other VEGF-C binding
receptors including NRP-1 and NRP-2 (Ka ¨rpa ¨nen et al, 2006) have
also been shown to mediate VEGF-C action. We found a partial
requirement of NRP-1 and NRP-2 for migratory function of MDA-
MB-231 cells, but not Hs578T cells. The mechanisms of NRP action
are complex. NRP-1 and NRP-2 are receptors for semaphorins, and
can antagonise semaphorin action by binding to and sequestering
VEGFs (Ellis, 2006; Guttmann-Raviv et al, 2006). NRP-binding
semaphorins 3A, 3B, and 3F exhibit antitumour properties, some
also described as migration inhibitory molecules (Bachelder et al,
2003; Nasarre et al, 2005). Thus, NRP-mediated pro-migratory
action on MDA-MB-231 breast cancer cells is likely a consequence
of endogenous VEGF-C binding. Since semaphorins are expressed
by breast cancer cell lines including MDA-MB-231, or present in
the breast cancer micro-environment in situ (Christensen et al,
2005), we suggest that our in vitro findings of NRP action are of
in vivo relevance. Differential expression of semaphorins may be
responsible for the differential effects of NRP-1/-2 gene knock-
down on cellular migration noted in MDA-MB-231 and Hs578T
cells in the present study. Another possible reason of this finding is
the differential expression of VEGFR-2 in these two cell lines
(Figure 2A), since the need for a cooperation between NRPs and
VEGFR-2 has been reported for certain NRP actions in other cells.
NRP-1 and NRP-2 are non-tyrosine kinase receptors which are
believed to transmit intracellular signals in conjunction with co-
receptor complexes involving plexin, VEGFR-1, or VEGFR-2 (Ellis,
2006; Guttmann-Raviv et al, 2006; Ochiumi et al, 2006). VEGFR-2
has been reported to interact with NRP-2 and promote the survival
and migration of HMVECs (Favier et al, 2006) and its interaction
with NRP-1 is needed for migration of human vascular smooth
muscle cells (Liu et al, 2005). Above-mentioned possibilities for
differential NRP actions in our breast cancer cell lines remain to be
tested.
Integrin a9b1 is another VEGF-C binding receptor expressed by
neutrophils (Shang et al, 1999), human epithelial, and muscle cells
(Palmer et al, 1993; Basora et al, 1998), and certain tumour cells
and tissues (Palmer et al, 1993; Basora et al, 1998; Vantyghem et al,
2005). This receptor has been reported to signal via the a9 chain to
promote cell migration (Young et al, 2001). Our results reveal that
VEGF-C producing Hs578T cells expressed integrin a9b1 at a level
higher than MDA-MB-231 cells. This is the only identifiable
receptor contributing to the migratory function of Hs578T cells, as
no VEGFR-2/-3 mRNA expression was seen in these cells and NRP-
1/-2 siRNAs failed to affect the migration of these cells. Since
Hs578T cells do not express osteopontin (Sharp et al, 1999) but
express tenascin-C (Dandachi et al, 2001) – the two other ligands
for integrin a9b1, the role of a9b1 in migration of these cells may
be attributed to endogenous VEGF-C or tenascin-C, or both.
However, since the inhibitory activity of a9b1 integrin antibody
was significant but rather moderate in comparison with VEGF-C
function blocking antibody, other unidentified VEGF-C binding
receptors may also be involved.
In summary, the present study shows that the migratory
function, an essential step for tumour invasion and metastasis, is
promoted in an autocrine fashion by endogenous VEGF-C
produced by metastatic human breast cancer cell lines, utilising
multiple VEGF-C receptors. Further studies are needed to establish
a firm link between the promigratory roles of VEGF-C and these
receptors as well as to identify precise signalling mechanisms
responsible for the autocrine role of VEGF-C mediated by different
VEGF-C receptors. Combined with our earlier reported data that
COX-2 and certain EP receptors (EP1 and EP4) are responsible
for promotion of cellular migration (Timoshenko et al, 2003) as
well as VEGF-C upregulation in human breast cancer
(Timoshenko et al, 2006), present results reinforce the place of
COX-2 inhibitors and specific EP antagonists in breast cancer
chemo-intervention.
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